Status:
UNKNOWN
The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF)
Lead Sponsor:
Medical Practice Prof D. Ivanov
Conditions:
Gout
CKD Stage 1-4
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
This trial aims to investigate the impact of two target levels uric acid-lowering therapy (ULT) caused by hyperuricemia (HU) on kidney function and CKD progression \[1\] measured by eGFR and albuminur...
Detailed Description
The background and rationale The extended 2016 EULAR updated report states \[2\] that for patients on ULT, SUA level should be monitored and maintained to \<6 mg/dL (360 µmol/L). A lower SUA target (\...
Eligibility Criteria
Inclusion
- outpatient adults withgout and hyperurecemia (SUA level above 8 mg/dL (480 µmol/L)
- outpatient adults with CKD 1-4 stages and hyperurecemia (SUA level above 8 mg/dL (480 µmol/L)
Exclusion
- CKD 5 stage
- heart failure III-IV NYHA
- stroke
- peripheral arterial disease
- obesity with BMI above 30 kg/m2
- hypertension 3 grade
- insulin-dependent DM
- any kind of cancer
- inpatient intensive unit patients.
Key Trial Info
Start Date :
October 30 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT03336203
Start Date
October 30 2017
End Date
December 31 2022
Last Update
August 24 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Practice Prof D.Ivanov
Kiev, Ukraine, 01014